# An Open-Label Study of the Safety of an Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients With AL Amyloidosis

> **NCT05692908** · PHASE1 · WITHDRAWN · sponsor: **Sorrento Therapeutics, Inc.**

## Conditions studied

- Light Chain (AL) Amyloidosis

## Interventions

- **BIOLOGICAL:** STI-6129

## Key facts

- **NCT ID:** NCT05692908
- **Lead sponsor:** Sorrento Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-09
- **Primary completion:** 2024-09
- **Final completion:** 2024-11
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sorrento Therapeutics filed for chapter 11 bankruptcy.
- **Last updated:** 2023-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05692908

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05692908, "An Open-Label Study of the Safety of an Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients With AL Amyloidosis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05692908. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*